Clinical Trial Update: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating BPI-16350 in combination with fulvestrant for HR+ HER2- locally advanced, recurrent, or metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• BPI-16350 (BPI-16350)
• Fulvestrant (fulvestrant)

Snippet

Sponsor: Betta Pharmaceuticals Co., Ltd. | Conditions: Breast Cancer | Phase 3 | Status: UNKNOWN